phosphorylcholine has been researched along with Sarcoma in 5 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins." | 9.12 | A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. ( Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R, 2006) |
| "A multicenter Phase II study was performed to evaluate the clinical activity of an initial loading (150 mg every 6 hours x 4 doses) dose followed by continuous daily oral dosing (100 mg/day) of perifosine in patients with advanced soft tissue sarcomas (STSs)." | 9.12 | Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. ( Bailey, HH; Erlichman, C; Ettinger, DS; Fracasso, PM; Mahoney, MR; Maples, WJ; Okuno, SH; Traynor, AM, 2006) |
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 9.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| "BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins." | 5.12 | A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. ( Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R, 2006) |
| "A multicenter Phase II study was performed to evaluate the clinical activity of an initial loading (150 mg every 6 hours x 4 doses) dose followed by continuous daily oral dosing (100 mg/day) of perifosine in patients with advanced soft tissue sarcomas (STSs)." | 5.12 | Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. ( Bailey, HH; Erlichman, C; Ettinger, DS; Fracasso, PM; Mahoney, MR; Maples, WJ; Okuno, SH; Traynor, AM, 2006) |
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 5.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| " In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed." | 2.67 | Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Liu, W | 1 |
| Poradosu, E | 1 |
| Ratain, MJ | 1 |
| Knowling, M | 1 |
| Blackstein, M | 1 |
| Tozer, R | 1 |
| Bramwell, V | 1 |
| Dancey, J | 1 |
| Dore, N | 1 |
| Matthews, S | 1 |
| Eisenhauer, E | 1 |
| Bailey, HH | 1 |
| Mahoney, MR | 1 |
| Ettinger, DS | 1 |
| Maples, WJ | 1 |
| Fracasso, PM | 1 |
| Traynor, AM | 1 |
| Erlichman, C | 1 |
| Okuno, SH | 1 |
| Pronk, LC | 1 |
| Planting, AS | 1 |
| Oosterom, R | 1 |
| Drogendijk, TE | 1 |
| Stoter, G | 1 |
| Verweij, J | 2 |
| Krzemieniecki, K | 1 |
| Kok, T | 1 |
| Poveda, A | 1 |
| van Pottelsberghe, C | 1 |
| van Glabbeke, M | 1 |
| Mouridsen, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma[NCT00053794] | Phase 2 | 17 participants (Actual) | Interventional | 2003-06-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for phosphorylcholine and Sarcoma
| Article | Year |
|---|---|
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Canada; Disease Progression; Female; H | 2006 |
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Hum | 2006 |
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, | 1994 |
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholin | 1993 |
1 other study available for phosphorylcholine and Sarcoma
| Article | Year |
|---|---|
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Dosage; Gene Expression Regulation, Neoplas | 2008 |